SynthesisRheumatology international2010
Fc receptor-like 3 -169 C/T polymorphism and RA susceptibility: a meta-analysis.
Synthesis in Rheumatology international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Fc receptor-like 3 (FCRL3) -169 C/T polymorphism and systemic lupus erythematosus: a meta-analysis.Rheumatology international · 2013Pooled it
- Exploration of potential novel drug targets for rheumatoid arthritis by plasma proteome screening.PLoS computational biology · 2025Article
- MHC2TA and FCRL3 genes are not associated with rheumatoid arthritis in Mexican patients.Rheumatology international · 2016Article
- Genetic associations of FCRL3 polymorphisms with the susceptibility of Graves ophthalmopathy in a Chinese population.International journal of clinical and experimental medicine · 2015Article
- A systems genetics approach provides a bridge from discovered genetic variants to biological pathways in rheumatoid arthritis.PloS one · 2011Article
- Expression of the autoimmune susceptibility gene FcRL3 on human regulatory T cells is associated with dysfunction and high levels of programmed cell death-1.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Fc receptor-like 3 (FCRL3) -169 C/T polymorphism has been reported to be associated with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), but with inconsistent results. The aim of this study was to explore whether the FCRL3 -169 C/T polymorphism confers susceptibility to RA and SLE. The authors conducted a random effect meta-analysis on the associations between the C/C (recessive effect) or C/C + C/T (dominant effect) genotype or the allele C of the FCRL3 -169 polymorphisms and RA or SLE in different populations. In total, 15 separate comparisons, 12 for RA and 3 for SLE, drawn from nine European and six Asian population samples were included in this meta-analysis. No association between RA and the FCRL3 C allele was found for all study subjects (OR = 1.064, 95% CI = 0.987-1.146, p = 0.107). However, stratification by ethnicity indicated that the FCRL3 C allele was significantly associated with RA in Asians (OR = 1.203, 95% CI = 1.097-31.319, p < 0.001). Conversely, no association was detected for this allele and RA in Europeans (OR = 0.997, 95% CI = 0.931-1.068, p = 0.933). The ORs for the C/C + C/T and C/C genotypes in these ethnic groups showed the same trends as the FCRL3 C allele. An association between SLE and the FCRL3 -169 A allele was found in all study subjects (OR = 1.115, 95% CI = 1.003-1.240, p = 0.043), but meta-analysis excluding studies with controls not in HWE did not show the association. This meta-analysis suggests that the FCRL3 -169 C/T polymorphism is a significant risk factor for RA in Asians, but not in Europeans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.